CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 137 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2014. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $94,000 | -56.1% | 475,000 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $214,000 | -10.5% | 475,000 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $239,000 | -78.4% | 475,000 | 0.0% | 0.00% | -75.0% |
| Q1 2018 | $1,107,000 | -17.9% | 475,000 | 0.0% | 0.00% | -20.0% |
| Q4 2017 | $1,349,000 | -0.7% | 475,000 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $1,359,000 | +15.9% | 475,000 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $1,173,000 | -31.6% | 475,000 | 0.0% | 0.01% | -28.6% |
| Q1 2017 | $1,715,000 | +2.0% | 475,000 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $1,682,000 | -12.4% | 475,000 | 0.0% | 0.01% | -12.5% |
| Q3 2016 | $1,919,000 | -8.0% | 475,000 | 0.0% | 0.01% | -11.1% |
| Q2 2016 | $2,085,000 | +16.1% | 475,000 | 0.0% | 0.01% | +12.5% |
| Q1 2016 | $1,796,000 | -87.9% | 475,000 | -50.0% | 0.01% | -74.2% |
| Q4 2015 | $14,896,000 | +197.5% | 950,000 | +100.0% | 0.03% | +47.6% |
| Q3 2015 | $5,007,000 | -51.6% | 475,000 | +15.9% | 0.02% | -47.5% |
| Q2 2015 | $10,340,000 | -9.5% | 410,000 | 0.0% | 0.04% | -11.1% |
| Q1 2015 | $11,427,000 | +52.7% | 410,000 | 0.0% | 0.04% | +55.2% |
| Q4 2014 | $7,483,000 | +40.8% | 410,000 | 0.0% | 0.03% | +38.1% |
| Q3 2014 | $5,314,000 | -20.6% | 410,000 | 0.0% | 0.02% | -22.2% |
| Q2 2014 | $6,691,000 | – | 410,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Byrne Asset Management LLC | 86 | $2,000 | 0.00% |